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Study: This study aims to investigate the effect of permissive hypertension, a deliberate raising of the Mean Arterial Pressure (MAP), on cerebral
perfusion in LVAD patients, as treatment of embolic stoke.
Methods: A Lumped Parameter Model (LPM) of the entire human circulation that includes pulmonary and systemic circulation, as well as the
four heart chambers, is modified to split the systemic circulation into the
lower body and upper body. The upper circulation is subsequently split
into the extracranial and intracranial vasculatures to study the perfusion
to the brain as a function of MAP, peripheral and intracranial resistances.
HVAD H-Q relationships are incorporated to model the instantaneous
LVAD response. The impact of MAP values within a wide range, caused by
changes in the systemic resistance, on intracranial flow rate is established.
Increased resistance in the intracranial vasculature is then set to mimic a
major embolic stroke, and its influence on cerebral perfusion is studied
for a wide range of LVAD speeds, baseline MAPs, and systemic resistances.
Results: Flow to the intracranial vasculature significantly decreases when
MAP is allowed to rise, at all LVAD speeds, consistent with the reduction
in LVAD output for higher afterload. While at higher speeds, total cardiac
output is higher and the fraction of total flow that goes to the brain is
also higher than for lower speeds, the net intracranial flow rate always
decreases with an increase in MAP. This remains true and is exaggerated
when intracranial resistance is increased to model an embolic stroke.
These results show how the increased sensitivity to afterload of thirdgeneration LVADs, compared to the native heart, invalidates the paradigm
that permissive hypertension can lead to an increase in cerebral perfusion. This study highlights the phenomenon that letting MAP increase in
LVAD patients as a treatment of embolic stroke could negatively affect
cerebral perfusion.

Study: The Impella Catheters require a heparin-containing purge solution
to maintain proper pump function by reducing the risk of biomaterial
deposition in the purge gaps. A bicarbonate-based purge solution (BBPS)
has been proposed as an alternative to a heparin-based purge solution. We review performance in patients supported to date with a BBPS
(heparin-induced thrombocytopenia patients were excluded from this
analysis).
Methods: This review includes patients (n=26) supported using sodium
bicarbonate (25 mEq/1L of D5W) in the purge from September 2020 to
February 2021. These patients were supported with BBPS post-operatively where heparin in the purge was not desired or were transitioned to
BBPS because of bleeding issues. Case data were collected from an internal database to develop the clinical narrative and cross-referenced against
Impella Controller data logs to assess purge trends and pump function.
Results: All pumps were switched to BBPS in the purge if not started
with BBPS (Figure 1A). The average time to initiating BBPS was 1.6 days
(excluding n=3 outliers where time to switching was >15 days). The
average duration of support with BBPS was 5 days and a maximum duration of 22 days (Figure 1B). Figure 1C shows clinical indications for use.
Purge pressure and purge flow remained stable while on BBPS (Figure
1D). In conclusion, this preliminary experience suggests the feasibility
of using BBPS to maintain purge patency, ensure pump motor reliability,
reduce bleeding risk, and simplify anticoagulation management. Use of
a BBPS may be a safe and effective alternative to heparin in the purge
for patients in which heparin is contraindicated or not feasible. More
patient experience and analysis are needed to evaluate how bicarbonate
compares to heparin in the purge for all patients.
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